With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Larry Lowe, 54, used to run 10km most days and played in a rock band, but is now in so much pain he lies in bed at night ...

The major U.S. stock market indexes are officially in overheated territory thanks to enthusiasm for artificial intelligence ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 14:10 Hrs [IST] Pfizer ...

Robert F. Kennedy, Jr. has been antivax for two decades. His fellow travelers are not happy about his leaving out vaccines in ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.